Takeda Dissolves Lung Cancer Drug Collaboration With Biotech CanBas
This article was originally published in PharmAsia News
Executive Summary
Takeda and Shizuoka-based biotech venture firm CanBas announced an end to a collaboration agreement over cancer drug candidate CBP501